5 hrs ago | AmericanBankingNews.com
Endo Pharmaceuticals Given "Neutral" Rating at Goldman Sachs
's stock had its "neutral" rating reaffirmed by research analysts at Goldman Sachs in a report released on Wednesday.
Healthcare Business Recap: Human Genome Sciences Shareholder Sues,...
The board of Human Genome Sciences is being sued by a shareholder, and the court is being petitioned to stop the company from using its "poison pill" to prevent the $2.6 billion hostile takeover attempt by GlaxoSmithKline .
Endo Health Solutions Inc. (Formerly Known as Endo Pharmaceuticals...
Endo Health Solutions Inc. to Present at Jefferies and Co. 2012 Global Healthcare Conference A live webcast and audio archive of the presentation will be available on the company's website at http://www.endo.com/ . Click on Investor Relations, and then the link to the Event and Presentation.
Watson, Endo and Teikoku Seiyaku enter settlement agreement to resolve Lidoderm patent litigation
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an agreement with Endo Pharmaceuticals Inc.
ENDP Makes Bullish Cross Above Critical Moving Average
In trading on Friday, shares of Endo Health Solutions Inc crossed above their 200 day moving average of $33.67, changing hands as high as $33.69 per share.
Endo Health Solutions Inc. Announced as New Name for Endo Pharmaceuticals Holdings Inc.
CHADDS FORD, Pa., May 23, 2012 /PRNewswire-FirstCall/ -- Shareholders of Endo Pharmaceuticals Holdings Inc.
BioDelivery Sciences Provides Business Review and Update in...
RALEIGH, N.C., May 10, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc.
Can Teva Win With The Big Pharma Playbook?
There's no question that Teva Pharmaceuticals rewarded long-term investors with years and years of growth as it became the world's largest generic drug manufacturer.
U.S. Senate probes painkiller makers, allie...
A U.S. Senate panel has launched a probe of possible links between three drugmakers and nonprofit medical groups that advocated for increasing the use of prescription painkillers, now the target of a nationwide law enforcement crackdown.
Endo Pharmaceuticals Given "Neutral" Rating at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a report released on Friday.
Endo to Present at Bank of America Merrill Lynch 2012 Health Care Conference
CHADDS FORD, Pa., May 4, 2012 /PRNewswire/ -- Endo today announced that Alan Levin, executive vice president and chief financial officer, will present a corporate overview at the Bank of America Merrill Lynch 2012 Heath Care Conference on Wednesday, May 16, 2012 at 12:20 p.m. ET.
Endo Pharmaceuticals Downgraded to "Hold" at Cantor Fitzgerald
Several other analysts have also recently commented on the stock. Analysts at Citigroup set a $48.00 price target on shares of Endo Pharmaceuticals in a research note to investors on Monday, March 26th.
Endo Pharmaceuticals Holdings' CEO Discusses Q1 2012 Results - Earnings Call Transcript
I'd now like to turn the call over to Mr. Blaine Davis, Senior Vice President of Corporate Affairs.
Endo Pharmaceuticals Holdings Inc. Reports First Quarter Financial...
Endo Pharmaceuticals Holdings Inc. Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA ER And Voltaren Gel , increased 23 percent versus prior year; Driven by full quarter addition of AMS as well as Qualitest revenue growth of 8 percent.